Cyclo Therapeutics (Nasdaq:CYTH) - Prezzo delle azioni, notizie e analisi

CYTH Panoramica delle azioni

CYTH analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 75.33% all'anno

Analisi del rischio

Patrimonio netto negativo

Ha meno di 1 anno di pista di cassa

Realizza un fatturato inferiore a 1 milione di dollari ( $871K )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

+ 3 più rischi

Cyclo Therapeutics, Inc. Concorrenti

Zeo ScientifiX

OTCPK:ZEOX

US$20.4m

Pieris Pharmaceuticals

NasdaqCM:PIRS

US$21.1m

OpGen

OTCPK:OPGN

US$15.1m

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Cyclo Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.73
Massimo di 52 settimane	US$2.12
Minimo di 52 settimane	US$0.59
Beta	-0.38
1Variazione di 1 mese	-2.67%
Variazione a 3 mesi	-6.41%
Variazione di 1 anno	-43.41%
3Variazione a 3 anni	-86.17%
Variazione a 5 anni	-97.19%
Variazione dall'IPO	-99.63%

Notizie e aggiornamenti recenti

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Rendimenti per gli azionisti

	CYTH	US Biotechs	US Mercato
7D	4.4%	2.4%	2.2%
1Y	-43.4%	16.2%	31.7%

Ritorno vs Industria: CYTH ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 16.2 % nell'ultimo anno.

Rendimento vs Mercato: CYTH ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.7 % nell'ultimo anno.

Volatilità dei prezzi

Is CYTH's price volatile compared to industry and market?
CYTH volatility
CYTH Average Weekly Movement	10.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di CYTH è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 10% ) di CYTH è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1990	8	N. Fine	cyclotherapeutics.com

Cyclo Therapeutics, Inc. è una società di biotecnologie in fase clinica, impegnata nello sviluppo di prodotti a base di ciclodestrine per il trattamento di malattie neurodegenerative. Il candidato farmaco principale dell'azienda è Trappsol Cyclo (idrossipropil beta ciclodestrina), un farmaco orfano, in fase di sperimentazione clinica di Fase III per il trattamento della malattia di Niemann-Pick di tipo C e in fase di sperimentazione clinica di Fase IIb per il trattamento della malattia di Alzheimer. L'azienda vende inoltre ciclodestrine e prodotti correlati all'industria farmaceutica, nutrizionale e di altro tipo, principalmente per l'uso nella diagnostica e nei farmaci speciali.

Cyclo Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Cyclo Therapeutics con la sua capitalizzazione di mercato?
CYTH statistiche fondamentali
Capitalizzazione di mercato	US$20.11m
Guadagni(TTM)	-US$24.80m
Ricavi(TTM)	US$870.73k

24.1x

Rapporto P/S

-0.8x

Rapporto P/E

CYTH è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CYTH Conto economico (TTM)
Ricavi	US$870.73k
Costo del fatturato	US$76.25k
Profitto lordo	US$794.48k
Altre spese	US$25.59m
Guadagni	-US$24.80m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.86
Margine lordo	91.24%
Margine di profitto netto	-2,848.16%
Rapporto debito/patrimonio netto	-90.4%

Come si è comportato CYTH nel lungo periodo?

Vedi performance storica e confronto

CYTH Panoramica delle azioni

Premi

Analisi del rischio

Cyclo Therapeutics, Inc. Concorrenti

OTCPK:ZEOX

US$20.4m

NasdaqCM:PIRS

US$21.1m

OTCPK:OPGN

US$15.1m

NasdaqCM:VBLT

US$12.1m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New major risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

Recent updates

New major risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo